Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Vidya Herbs Inc. is currently navigating 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. This portfolio is split between 2 distinct examiners, ensuring that the prosecution of each matter is handled independently. The involvement of 2 distinct art units further suggests that the company's biotechnology innovations may span different technical classifications, requiring a versatile approach to legal arguments. This distribution prevents any single examiner from having a disproportionate impact on the company's overall patent strategy. Prosecution in this area often faces rigorous scrutiny regarding enablement and written description, making the choice of art unit particularly significant.
The busiest examiner, WRIGHT, SARAH C, is currently overseeing 1 pending office action. With a total of 2 pending office actions, this means the workload is evenly divided among the 2 distinct examiners involved. For practitioners, this 1 to 2 ratio of the busiest examiner's load to the total portfolio indicates a balanced administrative environment. Success in these 2 distinct art units will depend on tailoring responses to the specific technical requirements of each examiner, as each handles exactly 1 pending office action. This focused distribution allows for detailed attention to the specific issues raised in each case.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WRIGHT, SARAH C | 1 | 42.1% | +45.6% |
| CHEN, CATHERYNE | 1 | 37.5% | +17.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19047471 | BISACURONE COMPOSITION AND METHOD OF SKIN WHITENING | WRIGHT, SARAH C | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19047471 | BISACURONE COMPOSITION AND METHOD OF SKIN WHITENING | WRIGHT, SARAH C | — |
| 19001403 | POLYPHENOL COMPOSITION AND METHOD OF ITS USE AND MANUFACTURE IN REDUCING BODY WEIGHT | CHEN, CATHERYNE | — |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| 1655 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19047471 | BISACURONE COMPOSITION AND METHOD OF SKIN WHITENING | WRIGHT, SARAH C | 1615 | §103§112Other | Non-Final OA | — | Pending | Feb 06, 2025 |
| 19001403 | POLYPHENOL COMPOSITION AND METHOD OF ITS USE AND MANUFACTURE IN REDUCING BODY WEIGHT | CHEN, CATHERYNE | 1655 | §102§112DP | Non-Final OA | — | Pending | Dec 24, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialVidya Herbs Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Sarah C Wright has the most, with 1 of Vidya Herbs Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
